



## Expedeon Announces Supervisory Board Changes

- **Dr. Cristina Garmendia Mendizábal to step down as chairwoman of the supervisory board**
- **Joseph Fernandez to assume responsibilities until a suitable successor is found**

**Heidelberg, Germany and Cambridge, UK, 14 March 2019** – Expedeon AG (Frankfurt: EXN; ISIN: DE000A1RFM03; Prime Standard) today announced that Dr. Cristina Garmendia Mendizábal is to step down as chairwoman of the supervisory board effective April 4, 2019. Dr. Garmendia will shortly be assuming a new role in Spain which she will be unable to combine with her duties at Expedeon AG. Dr. Garmendia will retain her entire shareholding in Expedeon. Joseph Fernandez, deputy chairman of the supervisory board will assume Dr. Garmendia's responsibilities until a suitable successor is found.

"We would like to thank Dr. Cristina Garmendia Mendizábal for her invaluable support during the exciting evolution of Expedeon which she has overseen during the past six years. We are very sad to see her leave and wish her great success in her new opportunity", **Dr. Heikki Lanckriet, CEO of Expedeon said.** "Also, I would like to thank Joseph Fernandez for his willingness to increase further his commitment to Expedeon. His industry knowledge and broad commercial expertise has been invaluable to the Company over recent years."

### For further information, please contact:

#### **Expedeon AG**

Dr. Heikki Lanckriet

CEO

Phone: +44 1223 873 364

Email: [heikki.lanckriet@expedeon.com](mailto:heikki.lanckriet@expedeon.com)

#### **MC Services AG (Investor Relations and International Media Relations)**

Raimund Gabriel

Managing Partner

Phone: +49 89 210228 0

Email: [expedeon@mc-services.eu](mailto:expedeon@mc-services.eu)

#### **About Expedeon AG: [www.expedeon.com](http://www.expedeon.com)**

Expedeon is an enabler of exciting advances in medical science and patient care. The Company's core technologies, innovative products and services are used in research laboratories around the world, enabling scientists to push the boundaries of research and product development, and play an integral part in new diagnostic tools being brought to market. With applications spanning the entire workflows in genomics, proteomics and immunology, Expedeon's technologies both accelerate and simplify research and make new and cost-effective processes available to biopharmaceutical and diagnostic organisations alike, thereby underpinning its customers' development and commercialisation objectives. Expedeon's products are sold through a direct sales force and several distribution partners in Europe, the USA and

Asia. Expedeon AG has offices in Germany, Spain, UK, USA and Singapore. The Company is listed on the Prime Standard segment of the Frankfurt Stock Exchange (Ticker: EXN; ISIN: DE000A1RFM03).

This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of Expedeon AG may deviate greatly from the established conclusions or implied predictions contained in such statements. Expedeon does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason.